Qiagen Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Qiagen kazanç ve gelirin sırasıyla yıllık 34.3% ve 7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 33.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 12.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

34.3%

Kazanç büyüme oranı

33.4%

EPS büyüme oranı

Life Sciences kazanç büyümesi18.6%
Gelir büyüme oranı7.0%
Gelecekteki özkaynak getirisi12.5%
Analist kapsamı

Good

Son güncelleme17 Oct 2024

Gelecekteki son büyüme güncellemeleri

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03
Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

Oct 11
Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

Sep 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

May 21
With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03
Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Mar 20
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04
A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31
We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Aug 25
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Jul 28
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Kazanç ve Gelir Büyüme Tahminleri

NYSE:QGEN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20262,23350152377415
12/31/20252,09043644761320
12/31/20241,97420929850319
6/30/20241,94073405576N/A
3/31/20241,939337358521N/A
12/31/20231,965341297459N/A
9/30/20231,956485302468N/A
6/30/20231,978337376519N/A
3/31/20231,999353430580N/A
12/31/20222,142423566715N/A
9/30/20222,226488660826N/A
6/30/20222,261539580770N/A
3/31/20222,313563556755N/A
12/31/20212,252513432639N/A
9/30/20212,240311516745N/A
6/30/20212,190480337592N/A
3/31/20212,065449239571N/A
12/31/20201,870359154458N/A
9/30/20201,71319110298N/A
6/30/20201,61214108333N/A
3/31/20201,550-31152302N/A
12/31/20191,526-4156331N/A
9/30/20191,516-2560332N/A
6/30/20191,51119658342N/A
3/31/20191,50718887356N/A
12/31/20181,502190209359N/A
9/30/20181,49690189325N/A
6/30/20181,48278189324N/A
3/31/20181,45355N/A275N/A
12/31/20171,41840N/A287N/A
9/30/20171,38789N/A311N/A
6/30/20171,36275N/A323N/A
3/31/20171,34782N/A353N/A
12/31/20161,33880N/A342N/A
9/30/20161,320123N/A328N/A
6/30/20161,296123N/A331N/A
3/31/20161,281126N/A303N/A
12/31/20151,281130N/A317N/A
9/30/20151,293104N/A310N/A
6/30/20151,315105N/A303N/A
3/31/20151,326113N/A305N/A
12/31/20141,345116N/A288N/A
9/30/20141,345151N/A291N/A
6/30/20141,331157N/A284N/A
3/31/20141,31572N/A259N/A
12/31/20131,30269N/A259N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: QGEN 'nin tahmini kazanç büyümesi (yıllık 34.3% ) tasarruf oranının ( 2.5% ) üzerindedir.

Kazançlar ve Piyasa: QGEN şirketinin kazançlarının (yıllık 34.3% ) US pazarından (yıllık 15.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: QGEN şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: QGEN şirketinin gelirinin (yıllık 7% ) US pazarından (yıllık 8.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: QGEN şirketinin gelirinin (yıllık 7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: QGEN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 12.5 %).


Büyüyen şirketleri keşfedin